Increase of RBP4 and PLAC8 expression in prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by OPG and the effect of RBP4 and PLAC8 knock-down on the growth of prostate cancer cells. Here, TNFRSF11B is linked to prostate carcinoma.